Sophie Cereja

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

Jean‐Jacques Kiladjian, Francisco Cervantes, Frank W.G. Leebeek et al. · Blood · 2008 · 355 citations · Full text

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Aurore Perrot, Cyrille Touzeau, Jérôme Lambert et al. · Blood · 2025 · 21 citations · Full text

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (<scp>APL</scp>): A prospective analysis by the <scp>F</scp>rench‐<scp>B</scp>elgian‐<scp>S</scp>wiss <scp>APL</scp> group

Thorsten Braun, Sophie Cereja, Sylvie Chevret et al. · Cancer · 2015 · 18 citations

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

Xavier Leleu, Guillemette Fouquet, Valentine Richez et al. · Clinical Cancer Research · 2019 · 14 citations · Full text

Light Chain Escape in Multiple Myeloma

Thomas Dejoie, Guillemette Fouquet, Cyrille Hulin et al. · Blood · 2018 · 11 citations